€12m to develop a Crohn’s therapy
Enlarge image


€12m to develop a Crohn’s therapy

27.11.2012 - French TxCell closes a third financing round. With €12.4m, the company will bring its T cell-based immunotherapy for Crohn’s disease into Phase III.

TxCell SA is a biotechnology company from Valbonne specialising in T cell-based immunotherapies for the treatment of severe chronic inflammatory diseases. On 26 November, it announced the successful closure of a third financing round for €12.4m. The money largely comes from the InnoBio fund. Managed by CDC Enterprises, the fund accounts for €6m. The remaining amount has been provided by TxCell’s existing shareholders Auriga Partners and Seventure Partners, two venture capital firms firmly rooted in France. Both VCs have a strong background in biotechnology. Auriga also financed lab equipment specialist Cytoo SA from Grenoble, Seventure a biofuel plant in Toulouse .

These additional financial resources will enable TxCell to pursue the development of its lead product candidate, Ovasave®. The antigen-specific Treg cell-based immunotherapy is for the treatment of Crohn’s disease in patients who are refractory to current treatments. Laurent Arthaud, Deputy CEO at CDC Entreprises said: “We are impressed by the innovative therapeutic approach and the encouraging positive clinical data obtained so far by TxCell. The company has a strong and experienced management team in place, and this capital injection will provide the necessary resources to confirm the clinical findings obtained so far and reach the next important development milestone.” To date, TxCell has completed a first in man Phase I/II clinical study that proved tolerability and efficacy of Ovasave®. 



24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


04.11.2015 What biotech stock market slump? Despite all odds, 2015 is set to become a new record year for the European public biotech sector, according to a BIOCOM-study presented at BIO Europe in Munich.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • THERAMETRICS (CH)0.05 CHF25.00%
  • MOLOGEN (D)4.10 EUR13.89%


  • DIAMYD MEDICAL -B- (S)8.75 SEK-5.91%
  • IMMUNICUM AB (S)40.60 SEK-5.80%
  • CELLECTIS (F)29.57 EUR-5.07%


  • PLETHORA (UK)5.50 GBP76.3%
  • PROTHENA PLC (IE)73.20 USD46.1%
  • CELLECTIS (F)29.57 EUR27.9%


  • EPIGENOMICS (D)1.84 EUR-59.3%
  • EVOCUTIS (UK)0.10 GBP-33.3%


  • KARO BIO (S)37.50 SEK5181.7%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)44.82 EUR249.1%


  • BIOTEST (D)15.03 EUR-81.4%
  • NEOVACS (F)0.72 EUR-79.1%

No liability assumed, Date: 25.11.2015